Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial - Cherney, D ZI; Zinman, B; Inzucchi, S E (Lancet Diab Endo, 2017)
et al.